Archive - Where Tech Meets Bio

Generative Diffusion in Molecular Design

A quick field guide to diffusion-based generators in molecular design—how they work, where they complement transformers, and who is deploying them today

Nov 27 •

Weekly Tech+Bio Highlights #64: Eli Lilly Reaches $1 Trillion Valuation

Merck's $3B AI drug discovery deal, new open-source virtual cell initiative, AI designing full-length antibodies, Europe’s first agentic AI…

Nov 25 •

and

Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development

Nov 20 •

Andrii Buvailo, PhD

Weekly Tech+Bio Highlights #63: Quantum vs. AI Small Molecule Design

FDA’s pathway for custom gene editing, UK’s non-animal testing roadmap, OpenAI leads a biosecurity seed, 100x mRNA delivery & over $1B in fresh life…

Nov 18 •

and

Protein Language Models: Builders & Pharma Deals

We unpack how PLMs work, notable builders, pharma deals, and current limitations

Nov 14 •

Weekly Tech+Bio Highlights #62: Virtual Biology, Open Co-Folding, and a World-Model Lab Agent

Neuralink's Rival raises $200M, AI healthcare funding at $10.7B in 2025, Lilly expands AI drug discovery via Insilico & XtalPi deals

Nov 10 •

and

New LLMs, Agents, and Graphs in Life Sciences

With Claude joining the lab, we survey healthcare LLMs, their real-world use, and how neurosymbolic AI can remedy their limitations

Nov 6 •

Weekly Tech+Bio Highlights # 61: Up to $2B for AI-Guided Blood-Brain Barrier Shuttles

Recursion’s Whole-Genome Microglia Map for Roche & Genentech; Roche x Manifold Bio BBB deal; Data Strategy & Model Architecture in Virtual Cells

Nov 3 •

and

October 2025

Weekly Tech+Bio Highlights #60: Eli Lilly & NVIDIA to Build AI Supercomputer for Drug Discovery

Anthropic brings Claude to Life Sciences, new NVIDIA-backed model may beat AlphaFold3, MIT ships open-source peptide binder & OpenFold gets a new…

Oct 28 •

and

How AI Powers Synthetic Biology

Let's face it, we are living in a "century of biology" and artificial intelligence is a growing enabler of what comes next

Oct 23 •

and

Weekly Tech+Bio Highlights #59: AI-Designed Cancer Drug Shows Early Responses

DeepMind & Yale release a 27B single-cell foundation model, an up to $1B protein design deal with Takeda, and Thermo Fisher adds OpenAI’s tools across…

Oct 20 •

and

Weekly Tech+Bio Highlights #58: Sanofi Licenses Neurosymbolic AI for Preclinical R&D

Precision Oncology Flywheel, ~$2.5B in Weekly Deal Value & Convergence of AI x CRISPR

Oct 14 •

and

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts